Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.2 USD | +9.93% | +16.98% | +26.79% |
May. 17 | Oppenheimer Initiates Capricor Therapeutics at Outperform Rating | MT |
May. 13 | Transcript : Capricor Therapeutics, Inc., Q1 2024 Earnings Call, May 13, 2024 |
Financials (USD)
Sales 2024 * | 26.58M | Sales 2025 * | 78.61M | Capitalization | 195M |
---|---|---|---|---|---|
Net income 2024 * | -33M | Net income 2025 * | -4M | EV / Sales 2024 * | 7.35 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 2.48 x |
P/E ratio 2024 * |
-5.99
x | P/E ratio 2025 * |
-27.2
x | Employees | 102 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.74% |
Latest transcript on Capricor Therapeutics, Inc.
1 day | +9.93% | ||
1 week | +16.98% | ||
Current month | +17.65% | ||
1 month | +23.75% | ||
3 months | +71.75% | ||
6 months | +103.95% | ||
Current year | +26.79% |
Managers | Title | Age | Since |
---|---|---|---|
Linda Marbán
CEO | Chief Executive Officer | 60 | 13-11-19 |
Anthony Bergmann
DFI | Director of Finance/CFO | 38 | 13-11-19 |
Kristi Elliott
CTO | Chief Tech/Sci/R&D Officer | - | 20-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Philip Gotwals
BRD | Director/Board Member | 61 | 23-07-20 |
Earl Collier
BRD | Director/Board Member | 76 | 13-11-19 |
George Dunbar
BRD | Director/Board Member | 77 | 13-11-19 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 6.2 | +9.93% | 755,112 |
24-05-16 | 5.64 | +5.82% | 505,314 |
24-05-15 | 5.33 | +2.50% | 284,300 |
24-05-14 | 5.2 | -4.41% | 667,284 |
24-05-13 | 5.44 | +2.64% | 193,872 |
Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+26.79% | 195M | |
+9.42% | 115B | |
+11.84% | 106B | |
-1.05% | 21.96B | |
-14.15% | 21.87B | |
-5.29% | 19.21B | |
-4.16% | 18.08B | |
-38.29% | 17.71B | |
+7.99% | 14.32B | |
+36.24% | 12.42B |
- Stock Market
- Equities
- CAPR Stock